BUY $PFE - NRPicks Ene 17
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. Pfizer mainly sells prescription drugs and vaccines, also spends a leading amount on research and development, close to $8 billion annually.
The company has developed its COVID-19 vaccine, however, it has not reflected its optimism in the stock price. The company has generated the same income quarter by quarter during the year, so we can see a good future for the development of its vaccine and the development of the new strain of the virus.
Fundamentals:
- Value
- P/B 3.1x VS 4.3x Industry
- ROE 22% vs. 17% industry
Technicians:
- Price level below SMA 250-200-150
- Williams R% at -50% levels
- RSI (40) Midlevel
- +1% average upside during the month
As a result of the allergic reactions to the vaccine presented, PFE presented a 15% correction from December 8 to December 31, which stopped at a support of $36.3. From this point on, the stock presented a change in trend, which could continue due to the fact that the stock is below its medium term moving average.
The company has developed its COVID-19 vaccine, however, it has not reflected its optimism in the stock price. The company has generated the same income quarter by quarter during the year, so we can see a good future for the development of its vaccine and the development of the new strain of the virus.
Fundamentals:
- Value
- P/B 3.1x VS 4.3x Industry
- ROE 22% vs. 17% industry
Technicians:
- Price level below SMA 250-200-150
- Williams R% at -50% levels
- RSI (40) Midlevel
- +1% average upside during the month
As a result of the allergic reactions to the vaccine presented, PFE presented a 15% correction from December 8 to December 31, which stopped at a support of $36.3. From this point on, the stock presented a change in trend, which could continue due to the fact that the stock is below its medium term moving average.
Exención de responsabilidad
La información y las publicaciones que ofrecemos, no implican ni constituyen un asesoramiento financiero, ni de inversión, trading o cualquier otro tipo de consejo o recomendación emitida o respaldada por TradingView. Puede obtener información adicional en las Condiciones de uso.